Article

Prostate doubling time may be valuable prognostic aid

The pace of prostate growth in a majority of men of northern European descent is as steady as a ticking clock and gives clinicians the opportunity to forecast prostate size in many patients with a single ultrasound measurement.

Related Videos
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Ravi Munver, MD, answers a question during a Zoom video interview
Interpreting ART toxicity and tolerability for bladder cancer, with Vedang Murthy, MD
1 KOL is featured in this series.
Related Content
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
October 11th 2024

Upper tract urothelial carcinoma: An in-depth review for urologists

Jesse Persily, MD Sameer Thakker, MD Katie S. Murray, DO, MS
"On-going innovation will continue to drive UTUC management forward, and with it will come on-going challenges of how to best study a relatively rare disease," write the authors.
Key updates from the AUA/ASRM male infertility guideline amendment
September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff
In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
October 10th 2024

Talazoparib/enzalutamide significantly boosts OS in mCRPC

Benjamin P. Saylor Jason M. Broderick Conor Killmurray
"The TALAPRO-2 results provide much-needed hope to patients who remain in high unmet need for effective treatment options," said Neeraj Agarwal, MD, FASCO.
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff
In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.
Bridget Koontz, MD: 18F-flotufolastat demonstrates high detection rate in low PSA setting
October 10th 2024

Bridget Koontz, MD: 18F-flotufolastat demonstrates high detection rate in low PSA setting

Urology Times staff
"We found that as soon as we got to the range of biochemical recurrence-defined PSA—0.2 ng/mL and up—the detection rate was very high," says Bridget Koontz, MD, FASTRO.
Phase 1/2 trial launches of Focal One robotic HIFU for BPH
October 9th 2024

Phase 1/2 trial launches of Focal One robotic HIFU for BPH

Hannah Clarke
“While there are other treatment options available for treating BPH, there remains a significant need for much less invasive treatment approaches that can preserve and protect the integrity of the urethra and other critical structures," says Ryan Rhodes.
© 2024 MJH Life Sciences

All rights reserved.